Dendritic cell activation and STAT6 phosphorylation are associated with Th2-biased immune dysregulation in asthma and are therapeutically targeted by suplatast tosilate
Letters in Drug Design & Discovery · 2026-10 · 100656
DOI: 10.1016/j.lddd.2026.100656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Drug Design & Discovery, 2026-10. Verfasst von Haojun Sha und 8 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Sha, H., Huang, H., Wen, Y., Rao, S., Chen, L., Yuan, W., Li, H., Xu, G., & Xie, C. (2026). Dendritic cell activation and STAT6 phosphorylation are associated with Th2-biased immune dysregulation in asthma and are therapeutically targeted by suplatast tosilate. Letters in Drug Design & Discovery, 100656. https://doi.org/10.1016/j.lddd.2026.100656
Vancouver
Sha H, Huang H, Wen Y, Rao S, Chen L, Yuan W, et al. Dendritic cell activation and STAT6 phosphorylation are associated with Th2-biased immune dysregulation in asthma and are therapeutically targeted by suplatast tosilate. Letters in Drug Design & Discovery. 2026:100656. doi:10.1016/j.lddd.2026.100656
BibTeX
@article{Sha2026,
author = {Sha, Haojun and Huang, Hao and Wen, Yongtao and Rao, Shuke and Chen, Lichong and Yuan, Weiliang and Li, Huafeng and Xu, Guihua and Xie, Chenli},
title = {Dendritic cell activation and STAT6 phosphorylation are associated with Th2-biased immune dysregulation in asthma and are therapeutically targeted by suplatast tosilate},
journal = {Letters in Drug Design & Discovery},
year = {2026},
pages = {100656},
doi = {10.1016/j.lddd.2026.100656}
}
EUVIMED